JAL Therapeutics Presents at First Look SoCal Innovation Showcase
June 4, 2024- JAL Therapeutics presented at the First Look SoCal Innovation Showcase, held at the Skirball Cultural Center in Los Angeles. The event, organized by the Alliance
News
JAL Therapeutics joins Academic Venture Exchange
March 1, 2024– JAL Therapeutics, a pioneering life sciences company focused on developing innovative treatments for Alzheimer’s disease and other chronic conditions, has joined the Academic Venture Exchange
California Life Sciences Innovation Showcase
JAL Therapeutics presented at the California Life Sciences (CLS) Innovation Showcase held at Bakar Labs on the campus of UC Berkeley. The event was an opportunity to connect with industry leaders, investors and entrepreneurs to culminate the company’s participation in the FAST California advisory program.
A Promising Covalent Approach to Treat Alzheimer’s Disease and CNS Disorders
JAL Therapeutics’ highly inhibitory, hyperselective, covalent approach to butyrylcholinesterase (BChE) inhibition may become the new frontier for treating and preventing Alzheimer’s disease, CNS disorders and other chronic conditions.
Alzheimer’s Drug Developer, JAL Therapeutics, Selected Into California Life Sciences, FAST Advisory Program
JAL Therapeutics’ highly inhibitory, hyperselective, covalent approach to butyrylcholinesterase (BChE) inhibition may become the new frontier for treating and preventing Alzheimer’s disease, CNS disorders and other chronic conditions.
JAL Therapeutics Presents Alzheimer’s Drug Candidate at Octane’s Medical Innovation Forum
October 8, 2022—JAL Therapeutics presented at the Octane Medical Innovation Forum, sharing company progress on its lead drug candidate. Octane is a convening organization of the technology and
JAL Therapeutics Presents at First Look SoCal Innovation Showcase
June 4, 2024- JAL Therapeutics presented at the First Look SoCal Innovation Showcase, held at the Skirball Cultural Center in Los Angeles. The event, organized by the Alliance for Southern
JAL Therapeutics joins Academic Venture Exchange
March 1, 2024– JAL Therapeutics, a pioneering life sciences company focused on developing innovative treatments for Alzheimer’s disease and other chronic conditions, has joined the Academic Venture Exchange (AVX). As
California Life Sciences Innovation Showcase
JAL Therapeutics presented at the California Life Sciences (CLS) Innovation Showcase held at Bakar Labs on the campus of UC Berkeley. The event was an opportunity to connect with industry leaders, investors and entrepreneurs to culminate the company’s participation in the FAST California advisory program.
A Promising Covalent Approach to Treat Alzheimer’s Disease and CNS Disorders
JAL Therapeutics’ highly inhibitory, hyperselective, covalent approach to butyrylcholinesterase (BChE) inhibition may become the new frontier for treating and preventing Alzheimer’s disease, CNS disorders and other chronic conditions.
Alzheimer’s Drug Developer, JAL Therapeutics, Selected Into California Life Sciences, FAST Advisory Program
JAL Therapeutics’ highly inhibitory, hyperselective, covalent approach to butyrylcholinesterase (BChE) inhibition may become the new frontier for treating and preventing Alzheimer’s disease, CNS disorders and other chronic conditions.
JAL Therapeutics Presents Alzheimer’s Drug Candidate at Octane’s Medical Innovation Forum
October 8, 2022—JAL Therapeutics presented at the Octane Medical Innovation Forum, sharing company progress on its lead drug candidate. Octane is a convening organization of the technology and medical technology
